Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05161195 | Roll-over Study to Allow Continued Access to Ribociclib | active not recruiting | Phase 4 | 134 | Novartis PharmaceuticalsINDUSTRY | 22 | Sep 18, 2026 | clinicaltrials |
| NCT06429761 | Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients(STRIDE) | active not recruiting | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06274515 | A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies(REMERGE) | recruiting | Phase 4 | 320 | Hoffmann-La RocheINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.(POG) | not yet recruiting | Phase 4 | 794 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07768358 | Tucatinib Continuation Study | not yet recruiting | Phase 4 | 175 | PfizerINDUSTRY | 0 | Aug 28, 2026 | clinicaltrials |
| NCT07257484 | Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors | recruiting | Phase 4 | 30 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04549207 | Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer | active not recruiting | Phase 4 | 240 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07490509 | Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer(DOSABEMA) | not yet recruiting | Phase 4 | 235 | Poitiers University HospitalOTHER | 0 | Jul 21, 2026 | clinicaltrials |
| NCT07252726 | Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers | recruiting | Phase 4 | 50 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05754528 | Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance(REaCT-TEMPO) | active not recruiting | Phase 4 | 240 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07600164 | Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer | recruiting | Phase 4 | 500 | Peking University People's HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07220967 | A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement | recruiting | Phase 4 | 392 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05753618 | Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy(REaCT-OGF) | recruiting | Phase 4 | 242 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06169371 | Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)(BRE-09) | recruiting | Phase 4 | 50 | University of Illinois at ChicagoOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05183126 | Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer | recruiting | Phase 4 | 22 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05376878 | An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis | recruiting | Phase 4 | 10 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04928261 | Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy | active not recruiting | Phase 4 | 52 | Ottawa Hospital Research InstituteOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07630948 | Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer(riboADHERE) | not yet recruiting | Phase 4 | 90 | Institute of Oncology LjubljanaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04921137 | Evaluating Harms and Benefits of Endocrine Therapy in Patients ≥70 Years of Age With Lower Risk Breast Cancer | recruiting | Phase 4 | 500 | Ottawa Hospital Research InstituteOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07583134 | Impact of Propranolol Strategies on Myocardial Injury After Breast Cancer Surgery(B-BIT) | not yet recruiting | Phase 4 | 100 | Chang-Ik YoonOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07589699 | Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP | not yet recruiting | Phase 4 | 59 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 15, 2026 | clinicaltrials |
| NCT07436663 | Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC(SGLT2i/DPPi) | not yet recruiting | Phase 4 | 150 | Tanta UniversityOTHER | 0 | Feb 27, 2026 | clinicaltrials |
| NCT07042581 | A Study of Revaree Plus in People With Breast Cancer | recruiting | Phase 4 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07344974 | Hand and Foot Bath for Taxane-Induced Peripheral Neurotoxicity | not yet recruiting | Phase 4 | 78 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07308717 | Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol | recruiting | Phase 4 | 1,896 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07254221 | Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients(ROSUBREAST) | not yet recruiting | Phase 4 | 400 | Shiraz University of Medical SciencesOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT06072807 | Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer | recruiting | Phase 4 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06574022 | Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks | recruiting | Phase 4 | 100 | University of CincinnatiOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06491680 | Cardiotoxicity in Breast Cancer Patients | recruiting | Phase 4 | 40 | Helwan UniversityOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT05871437 | Randomized Controlled Clinical Study on the Reduction of Tumor Marker Levels in Breast Cancer Patients by Huaier Granules | not yet recruiting | Phase 4 | 232 | Fudan UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05486182 | Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer(ESTROTIMP) | active not recruiting | Phase 4 | 153 | GE HealthcareINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07093931 | Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer | not yet recruiting | Phase 4 | 468 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05333328 | OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk(INTERSTELLAR) | recruiting | Phase 4 | 418 | Gangnam Severance HospitalOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT06920810 | Viscum Album for TNBC on Adjuvant Pembrolizumab(TNBNOBA) | recruiting | Phase 4 | 40 | Ilsan Cha hospitalOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT05465031 | Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM) | recruiting | Phase 4 | 600 | Silesian Centre for Heart DiseasesOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06868017 | Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles | not yet recruiting | Phase 4 | 208 | The First Hospital of Jilin UniversityOTHER | 0 | Mar 10, 2025 | clinicaltrials |
| NCT06777537 | Neoadjuvant Chemotherapy with or Without Talniflumate for the Treatment of Breast Cancer | not yet recruiting | Phase 4 | 200 | Shandong UniversityOTHER | 0 | Jan 16, 2025 | clinicaltrials |
| NCT06252662 | Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies | recruiting | Phase 4 | 200 | United States Naval Medical Center, PortsmouthFED | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06641544 | The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer(IFANS) | recruiting | Phase 4 | 200 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06613373 | An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer | not yet recruiting | Phase 4 | 30 | Jiangsu Famous Medical Technology Co., Ltd.INDUSTRY | 0 | Sep 25, 2024 | clinicaltrials |
| NCT06578299 | Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer | not yet recruiting | Phase 4 | 100 | Fudan UniversityOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT04790305 | Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer | recruiting | Phase 4 | 1,072 | Fudan UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06217185 | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | recruiting | Phase 4 | 100 | Hebei Medical University Fourth HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06245824 | Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial | not yet recruiting | Phase 4 | 51 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05860907 | Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis | not yet recruiting | Phase 4 | 384 | Fudan UniversityOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05843292 | Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer(NeoSTEP) | not yet recruiting | Phase 4 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT05841849 | Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer | not yet recruiting | Phase 4 | 1,028 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05452213 | Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients(CAPTOR-BC) | recruiting | Phase 4 | 1,000 | Institut fuer FrauengesundheitOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05420454 | A Study for the Neoadjuvant Treatment of Breast Cancer | recruiting | Phase 4 | 1,576 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 1, 2022 | clinicaltrials |
Data updated 12 days agoSource updated Sep 18, 2026source: clinicaltrials